(Q45787560)

16 December 2017

title

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses (English)

1 reference

16 December 2017

0 references

1 reference

1 reference

1 reference

1 reference

10

Paul A Rota

1 reference

16 December 2017

Azaibi Tamin

3

object named as

Azaibi Tamin

1 reference

16 December 2017

author name string

Matthias Liniger

1

1 reference

16 December 2017

Armando Zuniga

2

1 reference

16 December 2017

Teldja N Azzouz-Morin

4

1 reference

16 December 2017

Marlyse Knuchel

5

1 reference

16 December 2017

Rene R Marty

6

1 reference

16 December 2017

Marian Wiegand

7

1 reference

16 December 2017

Sara Weibel

8

1 reference

16 December 2017

David Kelvin

9

1 reference

16 December 2017

Hussein Y Naim

11

1 reference

16 December 2017

language of work or name

English

0 references

publication date

22 February 2008

1 reference

16 December 2017

published in

Vaccine

1 reference

16 December 2017

volume

26

1 reference

16 December 2017

issue

17

1 reference

16 December 2017

page(s)

2164-2174

1 reference

16 December 2017

Severe acute respiratory syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

The aetiology, origins, and diagnosis of severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

The SARS-CoV S glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Reverse Genetics Meets the Nonsegmented Negative-Strand RNA Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A recombinant measles virus expressing biologically active human interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Attenuated measles virus as a vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Measles virus and immunomodulation: molecular bases and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Role of virus strain dm conventional and enhanced measles plaque neutralization test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Effects of a SARS-associated coronavirus vaccine in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Medicine. Caution urged on SARS vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

SARS coronavirus: a new challenge for prevention and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

Chimeric measles viruses with a foreign envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.057

7 January 2021

inferred from DOI database lookup

Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus

1 reference

12 December 2020

Rescue of measles viruses from cloned DNA.

1 reference

12 December 2020

Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren

1 reference

12 December 2020

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

1 reference

12 December 2020

Measles virus spread and pathogenesis in genetically modified mice

1 reference

12 December 2020

Dendritic cells and measles virus infection.

1 reference

12 December 2020

A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice.

1 reference

12 December 2020

The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.

1 reference

12 December 2020

Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication.

1 reference

12 December 2020

10.1016/J.VACCINE.2008.01.057

Identifiers

DOI

1 reference

16 December 2017

0 references

1 reference

16 December 2017